Menopause and Tinnitus: What Causes It, What HRT Does, and What to Rule Out First
Route the ear concern before changing treatment
Find My HRT Path organizes your menopause symptoms, treatment preferences, risk history, insurance or cash-pay situation, and state—and flags when in-person care should come first.
How this page was verified → · Affiliate disclosure →
Menopause and tinnitus can arrive together, and hormone effects on the inner ear are biologically plausible. But no human study proves menopause directly causes tinnitus, and HRT is not an approved tinnitus treatment. Sudden hearing loss needs same-day care; one-sided or heartbeat-synchronous tinnitus needs prompt assessment. Most other patterns start with a hearing test and medication review.
Here's the part almost nobody tells you: the human evidence does not form a clean yes-or-no story. One large study found fewer diagnosis-coded tinnitus cases in HRT users. Another found more reported tinnitus with longer use. A US cohort linked longer oral hormone therapy with more self-reported hearing loss, while a new 2026 US study using objective audiometry found no independent HRT association. Small treatment reports suggest benefit, but none was a randomised placebo-controlled trial.
We'll show you the studies that change a real decision, side by side, with the numbers — and with the column that matters most: what each one cannot prove.
But first, the four questions you actually came here with.
| Your question | The bottom line |
|---|---|
| Can menopause cause tinnitus? | A link is plausible. Direct cause is not proven. Tinnitus prevalence rises with age, and hearing loss, noise, medicines, and other conditions still matter. |
| Will HRT fix it? | No hormone therapy is approved for tinnitus, and no randomised placebo-controlled trial has shown that menopausal HRT treats it. Do not start HRT for your ears. |
| What must not be missed? | Sudden hearing loss needs same-day care. New neurological symptoms need emergency care. One-sided or pulsatile tinnitus needs prompt assessment. |
| What actually helps? | Finding a treatable contributor, hearing aids when hearing loss is present, and cognitive behavioural therapy for tinnitus-related distress. |
This page is for you if you're roughly 40 to 60, the ringing is in both ears or has been present for weeks or months, and you're trying to work out whether menopause explains it and what to do next.
This is not your stop if your hearing dropped suddenly, the ringing arrived with new neurological symptoms, or you feel unable to keep yourself safe. Read the next box, then make the call. One-sided or heartbeat-synchronous ringing is not automatically an emergency when stable, but it still needs prompt assessment rather than a hormone explanation.
Which tinnitus patterns need same-day or emergency care?
Sudden hearing loss is the time-critical pattern. Tinnitus with a hearing drop over hours or a few days needs same-day medical assessment; new weakness, facial droop, speech change, double vision, or severe unsteadiness needs emergency care. Stable one-sided or pulsatile tinnitus usually needs prompt outpatient assessment, not automatic emergency-room care.
Get same-day medical care for:
- A sudden drop in hearing, in one or both ears, over hours or a few days — with or without ringing
- Tinnitus after a head injury, especially with hearing change, severe headache, vomiting, confusion, or loss of consciousness
- Tinnitus with severe ear pain, drainage, fever, or rapidly worsening symptoms
Call emergency services for:
- Ringing with new weakness, numbness, facial droop, double vision, slurred speech, loss of coordination, or severe unsteadiness
- Tinnitus-related distress with thoughts of self-harm or feeling unable to stay safe
Arrange prompt assessment for:
- New ringing in one ear only, especially with uneven hearing
- Ringing that pulses in time with your heartbeat
- Ringing with recurrent spinning vertigo, ear fullness, or fluctuating hearing
Why speed matters: sudden sensorineural hearing loss develops within a 72-hour window and is treated as a medical emergency. The AAO-HNSF guideline recommends hearing testing as soon as possible and within 14 days; corticosteroids may be offered within the first two weeks. If recovery is incomplete, intratympanic steroid salvage therapy is recommended two to six weeks after onset. NIDCD says treatment delayed more than two to four weeks is less likely to reverse or reduce permanent hearing loss.
This is not a complete list of symptoms that need urgent care. If the pattern is changing fast or something feels seriously wrong, get it assessed.
Sources: NIDCD Sudden Sensorineural Hearing Loss; AAO-HNSF Clinical Practice Guideline: Sudden Hearing Loss (Update), 2019; NICE NG155.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
We wrote this page because the usual answer frustrated us. It is often a soft "yes, hormones can affect your ears" followed by coping tips. That leaves out the questions that decide what happens next: which patterns are time-sensitive, what the hormone studies actually measured, which medication labels name tinnitus, and when the right first appointment is an audiogram rather than an HRT intake.
So we read the labels, trial records, cohort studies, and specialty guidelines ourselves. Everything below is dated and sourced.
Can menopause and tinnitus be directly linked?
Tinnitus is the perception of sound — ringing, hissing, buzzing, roaring, clicking, or pulsing — without a matching outside source. It can coincide with perimenopause, and estrogen receptors in inner-ear tissue make a hormone effect plausible. But no human trial shows that a menopause-related hormone change directly causes tinnitus. Plausibility is not a diagnosis.
There's a clean way to think about this. Three steps, and most pages stop at step two.
1. Timing is real. Your ears started ringing during a hormone transition. That happened. You're not making it up.
2. Plausibility is real. Estrogen receptors have been identified in inner-ear tissue, and auditory measures can vary across reproductive states. There is a biological route a hormone effect could travel down.
3. Proof is missing. Through 4 August 2026, we found no randomised human trial showing that a menopause-related hormone change directly generates tinnitus or that menopausal hormone therapy treats it.
Timing plus plausibility feels like proof. It isn't. And population data make the simple explanation harder to defend.
The test almost nobody runs
If falling estrogen were a dominant population-level cause, you might expect a clear female excess in tinnitus. The largest prevalence analysis assembled — 113 studies, published in JAMA Neurology in 2022 — did not find one overall.
| Group | Estimated tinnitus prevalence (95% CI) |
|---|---|
| All adults | 14.4% (12.6–16.5) |
| Men | 14.1% (11.6–17.0) |
| Women | 13.1% (10.5–16.2) — no statistically significant overall difference from men |
| Adults 18–44 | 9.7% (7.4–12.5) |
| Adults 45–64 | 13.7% (11.0–17.0) |
| Adults 65+ | 23.6% (19.4–28.5) |
| Severe tinnitus, all adults | 2.3% |
Source: Jarach CM, et al. Global Prevalence and Incidence of Tinnitus. JAMA Neurol. 2022;79(9):888–900.
Read those numbers again. The pooled estimate does not show an overall female excess. What climbs steeply is age — from roughly one in ten adults under 45 to nearly one in four over 65.
That analysis did not test whether women have a specific age-by-sex surge around the menopause transition, so it cannot close the hormone question. But it does weaken the simplest story that low estrogen alone explains the midlife rise.
The honest answer is: menopause may be one contributor, a timing marker, or a coincidence alongside several other contributors.
And that matters practically, not academically. Because here's what happens when you accept "it's just menopause": you stop looking. A medication effect, quiet hearing loss, heavy-bleeding-related iron deficiency, jaw involvement, migraine, or an ear disorder is exactly what gets missed next.
A number you'll see repeated — and where it comes from
Several menopause pages state that as many as one in three women in perimenopause or menopause have tinnitus. We traced that claim on 4 August 2026. We did not find a general-population study that supports a one-in-three prevalence estimate specifically for perimenopausal or menopausal women. There is a 33% figure in the literature. It comes from a 2025 cross-sectional study of 558 premenopausal women — women who had not reached menopause. The study found associations with secondary dysmenorrhea and menorrhagia. It cannot estimate tinnitus prevalence in menopause. The closest broad age-band figure in the global meta-analysis is 13.7% of adults aged 45–64, both sexes combined. We're flagging this instead of repeating it. If you're trying to work out whether ringing ears are "normal for menopause," the difference between one in three and about one in seven is the entire question.
One more thing worth knowing: perimenopause, menopause, and postmenopause are not the same. Perimenopause is the transition, when cycles can become unpredictable and hormones fluctuate. Menopause is confirmed after twelve months without a period when there is no other cause. Postmenopause is everything after. Some studies below involve premenopausal women, some postmenopausal women, and some women grouped only by age. Those populations cannot be treated as interchangeable.
When is ringing in your ears urgent?
Most tinnitus is not an emergency. Same-day care is for tinnitus with sudden hearing loss; emergency assessment is for new neurological signs or an immediate safety crisis. One-sided or pulsatile tinnitus needs prompt clinical and hearing assessment, but stable symptoms do not automatically require an emergency room. Long-standing bilateral tinnitus usually starts with routine evaluation.
Find your row.
| Pattern | What to do | Why |
|---|---|---|
| Sudden hearing loss, with or without ringing | Same-day medical care | Treatment timing can affect the chance of hearing recovery |
| Ringing plus sudden neurological signs | Emergency assessment | Stroke or another neurological cause must be ruled out |
| Ringing that pulses with your heartbeat | Prompt clinician or ENT assessment | Vascular, pressure-related, and structural causes may need investigation |
| Ringing in one ear only, or uneven hearing | Prompt hearing assessment; ENT depending on findings | One-sided patterns need targeted evaluation |
| Ringing with episodic spinning vertigo, fullness, or fluctuating hearing | Prompt hearing and ENT assessment | This pattern occurs in inner-ear disorders that need naming |
| Ringing in both ears, steady, no sudden hearing change | Routine hearing evaluation and medication review | Hearing loss, noise exposure, and medication effects are common starting points |
Source: AAO-HNSF Clinical Practice Guideline: Tinnitus (2014); AAO-HNSF Sudden Hearing Loss Update (2019); NICE NG155 (2020).
The tinnitus guideline recommends a prompt comprehensive hearing exam when tinnitus is one-sided, has persisted for six months or longer, or comes with any hearing difficulty. It recommends against routine imaging unless the tinnitus localises to one ear, pulses, comes with focal neurological signs, or accompanies asymmetric hearing loss.
That does not mean every one-sided case gets a scan. It means the clinician uses the hearing test, examination, and full pattern to decide whether imaging is appropriate.
What is not automatically an emergency
Some pages list so many warning signs that everything looks like a crisis. That's its own kind of harm — panic and paralysis aren't useful.
When these are the only features, they are not automatic reasons to rush to an emergency room:
- Ringing in both ears that has been steady for months
- Ringing that seems louder in a quiet room
- Ringing that varies with sleep, stress, or your attention
- Ringing with no sudden change in hearing
- Ringing that continues after menopause is behind you
- Feeling anxious while the ringing is present, without an immediate safety risk
They can still deserve an appointment. They do not all need one tonight.
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first — sudden hearing loss, new one-sided tinnitus, and pulsatile tinnitus are ear-care questions before provider-matching questions. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
Get my personalized HRT path →
About 90 seconds. No email or account. Nothing is sold or stored, and your health answers stay on the page. A licensed clinician makes all treatment decisions. Consumer health data privacy →
What does the research on menopause and tinnitus actually show?
The key human evidence is mixed and mostly observational. Premenopausal cycle studies show associations, postmenopausal HRT studies conflict, and the direct treatment literature consists of small nonrandomised or uncontrolled reports. Large hearing-loss studies also disagree and do not measure tinnitus. No randomised placebo-controlled trial has shown that menopausal HRT treats tinnitus.
The table below focuses on studies with direct tinnitus outcomes or large, clinically interpretable human hearing outcomes. The last column is the one that matters most — it tells you what each result cannot establish.
| Study | Who and how | What it found | What it cannot establish |
|---|---|---|---|
| Yu et al., 2019 · Scientific Reports | 4,633 premenopausal Korean women; nationwide cross-sectional survey | Tinnitus in 21.6%. Higher adjusted odds with irregular cycles: OR 1.37 (1.06–1.78) for intervals up to 3 months and OR 1.71 (1.03–2.85) beyond 3 months | Menopause causation, hormone levels, direction of effect, or treatment benefit |
| Zuriekat et al., 2025 · Scientific Reports | 558 premenopausal participants; cross-sectional questionnaire | 33% reported tinnitus; adjusted associations remained with secondary dysmenorrhea and menorrhagia | A menopause effect, an estrogen mechanism, anemia as the mediator, or prevalence in menopausal women |
| Chen et al., 2018 · Oncotarget | Taiwan insurance records; 13,920 HRT users vs 41,760 matched non-users, ages 45–79 | Diagnosis-coded tinnitus in 0.43% of HRT users vs 0.59% of non-users; adjusted HR 0.505 (0.342–0.756) | Prevention, symptom improvement, individual response, or freedom from residual confounding; it captures billed diagnoses, not all tinnitus |
| Lee et al., 2017 · BMJ Open | 2,736 Korean postmenopausal women; national survey with audiometry | Tinnitus in 22.2% overall; 20.3% with no HRT and 34.0% after 10+ years; adjusted OR 1.323 (1.007–1.737) | Whether HRT caused it; product, dose, route, timing, and reverse causation were unresolved |
| Zhao et al., 2017 | 59 perimenopausal women with chronic tinnitus; hormone treatment plus conventional tinnitus care vs conventional care alone | The hormone-treatment group reported larger improvement; 5 of 30 were classified as cured vs 0 of 29 controls | Randomised efficacy, blinding, placebo effect, durability, or relevance to current US regimens |
| Lai et al., 2017 · Clinical Otolaryngology | 13 selected menopausal women; retrospective and uncontrolled | Reported improvements in tinnitus scores after an older hormone regimen | Efficacy, safety, placebo comparison, generalisability, or relevance to current products |
| Liu et al., 2021 | 100 perimenopausal women with chronic tinnitus; treatment choice based on patient preference; tibolone for 3 months vs oryzanol | In the moderate-to-severe subgroup, tinnitus handicap and sleep scores improved in the tibolone group; hearing thresholds did not change | Randomised or blinded efficacy, placebo control, effects of current US MHT products, or benefit in mild tinnitus |
| Curhan et al., 2017 · Menopause | 80,972 US women; Nurses' Health Study II; 1.4 million person-years | Self-reported hearing loss, not tinnitus. Oral HT for 5–9.9 years: RR 1.15 (1.06–1.24); 10+ years: RR 1.21 (1.07–1.37) | Anything directly about tinnitus; objective hearing thresholds; causation |
| Hsu et al., 2026 · Annals of Otology, Rhinology & Laryngology | 1,778 US women ages 40–69; NHANES cross-sectional analysis with objective audiometry | Menopausal status was not independently associated with hearing loss: β 0.92 dB (−1.02 to 2.86). Among postmenopausal women, HRT use was also not associated: β 0.45 dB (−1.69 to 2.58) | Tinnitus, causation, effects of a specific product or route, or effects by treatment duration |
| Fu et al., 2025 · Maturitas | 214,327 UK Biobank women; prospective hearing-loss analysis | Menopausal hormone therapy was associated with higher hearing-loss risk after typical-age natural menopause, but not statistically clearly after premature or late menopause | Tinnitus, a product- or route-specific effect, individual treatment response, or freedom from healthy-user and prescribing bias |
| Jang et al., 2025 · Maturitas | 4,448 Korean women; objective hearing trajectories across the menopause transition | Hearing was relatively stable before the final menstrual period and declined afterward; reported HT use was not independently associated with hearing thresholds | Tinnitus, causation, a specific product effect, or whether treating menopause alters the trajectory |
How to read that table if the statistics aren't your thing:
- OR, HR, and RR compare groups. Above 1 means more of the outcome; below 1 means less.
- A 95% confidence interval is the range of values compatible with the data under the study model. For ratios, an interval crossing 1 does not show a statistically clear group difference. For a beta estimate, an interval crossing 0 does not show a statistically clear difference.
- Cross-sectional means a snapshot in time. It cannot show what came first.
- Cohort means records or people were followed over time. That is stronger for timing, but it is still not a randomised trial.
- Statistical significance does not turn an association into causation.
Scope note: this is not every paper on reproductive hormones and auditory physiology. We selected studies with direct tinnitus outcomes or large, clinically interpretable human hearing outcomes. Smaller audiometry, auditory-brainstem-response, and risk-factor studies exist, but they do not establish menopause as a tinnitus cause or HRT as a tinnitus treatment.
Does HRT help tinnitus — or cause it?
No hormone therapy is FDA-approved to treat tinnitus, and we found no randomised placebo-controlled trial showing that menopausal HRT treats it. The observational findings conflict across tinnitus, hearing-loss, and hearing-threshold outcomes. Small treatment reports suggest possible benefit in selected women, but their designs are too weak to turn HRT into an ear treatment.
We need to say something plainly here, because it is what you came to find out and it is not what a site like ours is expected to say.
The honest part
Starting hormone therapy to fix ringing in your ears is not a supported plan.
It is not an approved use. There is no randomised placebo-controlled trial showing it works. And the studies are too different to count as votes.
| Study | Outcome measured | Direction of association | The catch |
|---|---|---|---|
| Lee 2017 (n=2,736) | Self-reported tinnitus | More tinnitus with longer HRT use; 34.0% after 10+ years vs 20.3% with no HRT | Cross-sectional; product, route, dose, timing, and reason for treatment unresolved |
| Chen 2018 (n=55,680) | Diagnosis-coded tinnitus | Fewer coded tinnitus diagnoses in HRT users; adjusted HR 0.505 | Captured billed diagnoses, not all tinnitus symptoms; residual confounding remains |
| Curhan 2017 (n=80,972) | Self-reported hearing loss | More hearing loss with longer oral hormone therapy | Hearing loss is not tinnitus; outcome was self-reported; transdermal therapy was not the exposure |
| Hsu 2026 (n=1,778) | Objective audiometric hearing thresholds | No independent association between HRT use and hearing loss | Cross-sectional; no tinnitus outcome; product, route, and duration unresolved |
| Fu 2025 (n=214,327) | Incident hearing loss | MHT was associated with higher risk after typical-age natural menopause, but not statistically clearly after premature or late menopause | Hearing loss rather than tinnitus; no product- or route-specific tinnitus effect; observational prescribing bias remains possible |
| Jang 2025 (n=4,448) | Objective hearing trajectories | Hearing declined after the final menstrual period; reported HT use was not independently associated | No tinnitus outcome; no product-specific treatment effect |
Now the part that changes how you read the Taiwan result
The Taiwan study found diagnosis-coded tinnitus in 0.43% of HRT users and 0.59% of non-users over ten years. The absolute difference was 0.16 percentage points.
The best global prevalence estimate is around 14% of adults. Those figures are not directly comparable — one is diagnosis-coded incidence in a healthcare database and the other is pooled symptom prevalence — but the contrast tells you what the Taiwan database could actually see. It saw the small slice of tinnitus that became a billing diagnosis, not every woman hearing a sound in a quiet room.
That does not make the study worthless. It makes it a study about recorded tinnitus diagnoses in one healthcare system, not proof that HRT prevents or treats tinnitus.
The Korean survey has the opposite problem. It could see self-reported tinnitus, but it could not tell which product, dose, route, or treatment reason applied to each woman, or whether women with symptoms stayed on therapy differently from women without them.
Curhan and Fu measured hearing loss, not tinnitus. Hsu and Jang used objective hearing measures, which is a strength, but neither established a product-specific HRT effect. These studies answer related questions. They do not become one clean answer merely because they all contain the words menopause, hormone therapy, and hearing.
What about the studies that reported improvement?
They belong on the page. They also need their limitations beside them.
- Zhao 2017 reported more improvement in a 30-person hormone-treatment group than in 29 controls, but the report does not establish random allocation, blinding, a sham treatment, or relevance to current US menopause regimens.
- Lai 2017 described 13 selected cases with improvement after an older hormone regimen. There was no control group.
- Liu 2021 compared tibolone with oryzanol in 100 women whose treatment was selected by patient preference. Moderate-to-severe tinnitus and sleep scores improved in the tibolone group, but hearing thresholds did not; the study was not randomised or blinded.
Those results are signals worth researching. They are not a treatment recommendation.
So where does that leave you?
- Direct tinnitus studies point in different directions.
- Large hearing-loss and hearing-threshold studies also conflict.
- The apparent treatment studies are small, nonrandomised, uncontrolled, or based on older/non-US regimens.
- We found no randomised placebo-controlled HRT trial that settles whether HRT treats tinnitus.
If ringing ears are your only menopause symptom, hormone therapy is not the answer to them.
And here is why that is actually useful
The order of operations matters more than a hormone recommendation would.
Everything with stronger clinical support — a hearing test, a medication review, treatment of an identifiable contributor, CBT for tinnitus-related distress, and hearing aids when hearing loss is documented — is available without making a hormone decision first.
If you are considering hormone therapy anyway for hot flashes, night sweats, sleep disruption, or genitourinary symptoms, this evidence still earns its keep. It gives you specific questions for the prescriber: what the treatment is meant to improve, which route and product fit your recognised menopause symptoms and risk history, and how to review the timeline if tinnitus changed after starting, stopping, or adjusting treatment.
If tinnitus is your only symptom, you can stop reading the hormone sections. This is not a hormone decision. If ringing ears are one of several things going on — hot flashes, broken sleep, mood changes, painful sex — that is a different conversation, and it is worth having properly. The HRT Index's Find My HRT Path tool maps your symptoms, route preference, risk history, insurance, and state, then flags when online care is not the right starting point. Map my HRT questions before a consult →
Does it matter which hormone therapy you are taking?
Some older evidence raises a question about the progestogen component, but it does not establish that progesterone or a progestin causes tinnitus or that switching improves it. One small retrospective human hearing study, one mouse study, and a progesterone label report are signals of very different strength. They support a prescriber conversation — not a self-directed change.
Quick definition, because we are about to use it a lot. Progestogen is the umbrella term for progesterone and progestins. For most women who still have a uterus and use systemic estrogen, adequate progestogen or another clinician-directed endometrial-protection plan is needed to reduce the risk of endometrial hyperplasia and cancer.
Here is what the three signals show:
| Where it comes from | What it found | How much weight it carries |
|---|---|---|
| *Guimaraes et al., PNAS 2006* | 124 postmenopausal women ages 60–86. The estrogen-plus-progestin group had poorer hearing measures than the estrogen-alone and no-therapy groups | Retrospective, small, older population, older treatment patterns; hearing rather than tinnitus |
| *Price et al., Hearing Research 2009* | In perimenopausal mice, hearing measures worsened more in the estrogen-plus-progestin group than in estrogen-alone or placebo groups | Animal study; it cannot predict an individual woman's response |
| Current Prometrium label | Tinnitus and vertigo appear in the postmarketing adverse-event list | Voluntary reports; frequency and causality cannot be determined; not comparative evidence |
Three entries. Not three votes.
The human study and animal study raise a component question. The label says an event was reported after marketing. A postmarketing list does not show that the medicine caused it, how often it happens, or whether the same pattern applies to another progesterone or progestin.
We also checked the current oral Premarin prescribing information. Tinnitus does not appear in its adverse-reaction or postmarketing sections. That negative label check is not proof that conjugated estrogens cannot affect tinnitus; it only means the current label does not name it.
What you can and cannot do with this
Do not drop the progestogen that protects your uterine lining. If you have a uterus and use systemic estrogen, removing endometrial protection can create a real risk. A tinnitus theory is not a reason to improvise with that part of your prescription.
Do raise it as a question. Something like:
"My tinnitus changed around the same time as my hormone regimen. Can we review the exact product, route, dose, schedule, and whether another medically appropriate option would still protect my uterus and treat the symptoms we are targeting?"
That is a conversation about options. It is completely different from stopping.
On route: Curhan's hearing-loss finding was in oral hormone therapy. Fu reported an association for menopausal hormone therapy after typical-age natural menopause but did not establish a route-specific tinnitus effect. Neither study proves that a patch, gel, or spray is safer for the ears, and no route has been shown to treat tinnitus. Anyone telling you to switch routes specifically to fix ringing is going beyond the evidence.
On FDA-approved versus compounded hormones: no compounded drug is FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, and no evidence establishes a compounded hormone product as safer, more effective, or preferable for tinnitus. This page keeps FDA-approved and compounded options strictly separate and does not treat them as interchangeable.
One hard line: if tinnitus began or clearly changed after starting, stopping, or changing hormone therapy, record the exact dates and contact the prescriber. Do not use abrupt starts, stops, or dose changes as a home experiment. A supervised review can weigh the timeline, treatment goal, product, route, other medicines, and hearing at the same time. An article cannot.
Could a medication be contributing to the ringing?
Yes. Current labels and trial records for medicines used around menopause name tinnitus in specific places, but an entry is a signal, not proof of cause. Some generic paroxetine labels list tinnitus among reported adverse events and discontinuation reactions; Prometrium lists tinnitus and vertigo postmarketing. The useful evidence is your exact start, stop, dose-change, and symptom timeline.
This is the section we are proudest of, because some medications can cause tinnitus is not enough to act on.
So we opened the current labels and the registered trial results.
The Menopause Drug Tinnitus Ledger
FDA labels and registered results checked 4 August 2026.
| Medication or exposure | Why it appears in menopause care | What the current source says about tinnitus | What that means — and does not mean |
|---|---|---|---|
| Brisdelle (paroxetine mesylate 7.5 mg) | FDA-approved for moderate-to-severe vasomotor symptoms due to menopause | The registered 24-week study NCT01101841 reports tinnitus in 3 of 285 women (1.05%) on Brisdelle and 0 of 285 on placebo. The current approved label does not list tinnitus among common adverse reactions | The trial registry is a real signal, but three events do not establish a stable risk estimate or individual causation |
| Paroxetine tablets | Sometimes used off-label for hot flashes; other products are used for psychiatric indications | Some current generic labels list "Frequent: Tinnitus" under Special Senses | This is the label's event-frequency category from its adverse-event database, not a placebo-adjusted tinnitus risk at a menopause dose |
| Paroxetine — on stopping | Includes paroxetine products used for hot flashes or psychiatric indications | Tinnitus is listed among reactions reported after discontinuation, particularly abrupt discontinuation; labels advise gradual dose reduction | Do not quit cold. A taper is a prescriber decision |
| Venlafaxine — on stopping | Commonly used off-label for hot flashes | Current labeling lists tinnitus among discontinuation reactions and recommends gradual dose reduction | A discontinuation warning does not mean tinnitus is a common effect while taking it |
| Prometrium (micronized progesterone) | Endometrial protection with estrogen in women with a uterus; also indicated for secondary amenorrhea | Postmarketing reports include tinnitus and vertigo | Voluntary reports cannot establish frequency or causality |
| Premarin (conjugated estrogens) | FDA-approved estrogen product used for recognised menopause indications | Tinnitus does not appear in the current adverse-reaction or postmarketing sections we checked | A negative label check is not proof of zero risk |
| Veozah (fezolinetant) and Lynkuet (elinzanetant) | FDA-approved nonhormonal treatments for moderate-to-severe vasomotor symptoms | Tinnitus does not appear in their current common-adverse-reaction tables | Absence from a common-reaction table does not prove the event cannot occur |
| High-dose or sustained aspirin and some NSAID exposure | Not menopause-specific, but common in midlife | Tinnitus is a recognised dose-related ototoxic effect for salicylates and can occur with some other medicines | The full medicine, dose, duration, and hearing history matter; do not stop a prescribed medicine without guidance |
A correction that matters: Brisdelle is not the only FDA-approved nonhormonal prescription treatment for menopausal vasomotor symptoms. FDA approved Veozah (fezolinetant) in May 2023 and Lynkuet (elinzanetant) in October 2025. None is an approved tinnitus treatment.
Three things you must not take away from that table
1. Do not stop or change a dose on your own. Every row is a timing question for a prescriber or pharmacist, not an instruction.
*2. Starting and stopping can matter. Please do not read paroxetine lists tinnitus* and quit it cold. Abrupt discontinuation is itself a labelled route to tinnitus and other symptoms.
3. "Listed on a label" is not the same as "caused by the drug." Postmarketing lists are voluntary reports. Trial adverse-event lists include events observed during a study without proving the medicine caused them. A listing means the timing deserves review, not that the medicine is guilty.
The useful question is not "is my medicine on an internet list?" It is: "Did the onset, stop, dose change, and source information make this a credible contributor in my case?"
A pharmacist or prescriber can review that timeline. Bring everything: prescriptions, over-the-counter medicines, supplements, recent antibiotics, pain relievers, and anything you stopped.
Copy this into your appointment notes:
| Date | Medicine or supplement | Started, stopped, or dose changed? | Tinnitus or hearing change after it |
|---|---|---|---|
What should be checked before you blame hormones?
Start with the things the pattern can actually identify: hearing loss, noise exposure, ear disease, and medication timing. Iron deficiency or thyroid disease may matter when bleeding history, fatigue, breathlessness, palpitations, weight change, or other clues support them, but tinnitus guidelines do not require universal blood panels. The workup should follow your history, not a menopause theory.
1. A hearing loss you have not noticed
Tinnitus and hearing loss often travel together. High-frequency loss is sneaky — you hear one-to-one conversation and lose the thread in a restaurant. You turn subtitles on. You watch mouths. You blame the room.
An audiogram is the fastest way to stop guessing.
2. Your medication and noise timeline
Include medicines you started, stopped, or changed, including over-the-counter pain relievers and supplements. Also include concerts, power tools, firearms, loud workplaces, earbuds, and any single blast or sustained exposure.
A medication name without timing is weak evidence. A dose change followed by a symptom change is still not proof, but it is much more useful.
3. Iron deficiency — especially after heavy bleeding
This is the finding that connects two things most pages leave in separate boxes.
| Study | Design | Finding |
|---|---|---|
| *Hung et al., Frontiers in Nutrition, 2025* | Multi-institutional health-record cohort; 88,941 matched women in each group. Iron deficiency anemia required hemoglobin below 12 g/dL and ferritin below 30 ng/mL | New tinnitus at one year: HR 3.78 (2.60–5.50); incidence 15.7 vs 4.2 per 10,000 person-years. Severe anemia below hemoglobin 10 g/dL: HR 5.74 (3.24–10.16) |
| *Chen et al., Frontiers in Nutrition, 2025* | Multi-institutional cohort; 71,003 matched pairs | Hearing loss at one year: HR 2.79 (2.00–3.88); at three years: HR 1.56 (1.35–1.79) |
Both are observational health-record analyses. They show association, not cause. They cannot tell you that iron treatment will cure tinnitus.
Now connect the history.
Heavy or prolonged bleeding can occur during perimenopause and can lead to iron deficiency. The 2025 premenopausal tinnitus study found an association with menorrhagia but did not measure anemia. The separate 2025 cohort found a strong association between iron deficiency anemia and new diagnosis-coded tinnitus.
That creates a plausible chain:
heavy bleeding → iron deficiency anemia → higher tinnitus risk
It is not proof that this is your chain. But if you have heavy bleeding plus fatigue, breathlessness, palpitations, headaches, restless legs, or pulsatile tinnitus, that history belongs in front of the clinician. It is far more actionable than saying only, "I think my estrogen is low."
Heavy bleeding during perimenopause deserves its own plan →
4. Ear, jaw, migraine, and systemic clues
Tinnitus can also travel with things that have nothing to do with menopause:
| Clue | What it can point toward | Reasonable starting point |
|---|---|---|
| Ear blockage, pain, drainage, or recent infection | Wax, outer- or middle-ear disease, pressure problems | Ear examination; urgent if severe or rapidly worsening |
| Changes when you clench your jaw, grind your teeth, or move your neck | Somatic tinnitus, temporomandibular-joint or cervical involvement | Dentist, primary care, audiology, or ENT depending on the rest of the pattern |
| Headache, light sensitivity, aura, or vertigo | Migraine-related symptoms or another neurological or vestibular pattern | Primary care, neurology, or ENT depending on severity and red flags |
| Episodic spinning vertigo, ear fullness, fluctuating hearing | Ménière's disease or another inner-ear disorder | Hearing test and ENT assessment |
| Thyroid symptoms or known thyroid disease | A systemic contributor worth targeted review | Primary care and history-directed testing |
The direct evidence for thyroid disease is less specific than the hearing, medication, and iron evidence. That is why it belongs in targeted assessment, not as a universal tinnitus blood test.
Why a hormone panel cannot diagnose your ears
A serum estrogen, progesterone, or FSH result cannot establish that menopause caused tinnitus. Hormone levels fluctuate through perimenopause, and the menopause transition is usually diagnosed from age, menstrual history, and symptoms rather than a single panel. Testing can be appropriate in selected situations — especially at younger ages or when another diagnosis is possible — but there is no validated menopause tinnitus panel.
Anyone selling a blood panel as proof that low estrogen caused ringing in your ears is promising an answer the test cannot provide.
Is your hearing actually changing, or does it just feel that way?
Tinnitus and hearing loss overlap often enough that specialty guidance recommends a prompt hearing test when tinnitus is one-sided, has lasted six months or more, or comes with hearing difficulty. Many midlife women have high-frequency loss they have not named because ordinary conversation still sounds clear. An audiogram turns that vague suspicion into a usable result.
Here is what a high-frequency dip can feel like from the inside. See if it sounds familiar.
You are fine one-to-one. You are fine on the phone. But in a restaurant, a group, or with the television on, you are working. You are watching mouths. You are asking people to repeat themselves and then pretending you caught it the second time. You have started saying, "It is just loud in here."
That is the pattern. People often do not call it hearing loss because they can hear.
One proposed explanation for tinnitus is that reduced input from part of the auditory system changes how the brain processes sound. That model helps explain why tinnitus and hearing loss often coexist, but it does not identify the cause in an individual.
What actually happens at a hearing test
We are spelling this out because the mystery is the reason people put it off.
You sit in a quiet booth. You wear headphones. Tones play at different pitches and volumes, and you respond when you hear one. There may be a word-repetition test, bone-conduction testing, and a pressure test of the eardrum. The appointment commonly takes around 30 to 60 minutes, depending on what is included.
No needles. No dye. No machine you go inside. You leave with a chart.
That chart is one of the most useful things you can put in front of a clinician about this symptom. It also determines whether hearing aids — which have a guideline-supported role when tinnitus comes with documented hearing loss — are even on the table.
You have decided you need the assessment. Now the annoying part: finding one. Sesame lets you search available clinicians and see the listed visit price before booking. Its homepage says visits start at $34, but that is a platform-wide floor — not a verified ENT or audiology price. Specialist availability, services, and cost vary by ZIP code and provider. Search local appointment availability → We may earn a commission if you book through this link, at no cost to you. It does not change the recommendation to get ear-specific care. How we make money → Honest limitation: confirm that the listing provides the assessment you need. A video visit cannot perform an audiogram, and an ENT visit does not automatically include one. Insurance, a primary-care referral, a local audiology clinic, or a hearing center may cost less.
What does your tinnitus pattern point to?
The most useful description is the pattern, not the poetry of the sound. Which ear, pulsing or steady, sudden or gradual, with or without hearing change, and what changed in your medicine or noise exposure — those answers alter the starting point and urgency. "Ringing" versus "hissing" usually does much less diagnostic work.
Every page opens with what does it sound like? Ringing, hissing, buzzing, roaring. It is not the first question that routes care. Pattern does.
| Pattern | What it can point toward | Where to start | Urgency |
|---|---|---|---|
| Both ears, gradual, no sudden hearing change | Age-related or noise-related hearing change, medication exposure, sleep-attention loop; hormones remain a possible contributor rather than a diagnosis | Routine hearing test and medication/noise review | Routine |
| Started after a medicine was started, stopped, or changed | Medication effect or discontinuation reaction | Prescriber or pharmacist; bring exact dates and doses | Prompt if persistent or worsening; same day if hearing dropped suddenly |
| One ear only | A one-sided auditory or structural cause that needs targeted assessment | Prompt audiogram; ENT based on findings | Prompt, not automatically emergency |
| Pulses with your heartbeat | Vascular, pressure-related, structural, or systemic causes; anemia can be one contributor | Prompt medical assessment; imaging is decided from the full evaluation | Prompt |
| Sudden hearing drop over hours to days | Possible sudden sensorineural hearing loss | Same-day medical care | Time-critical |
| With spinning vertigo, fullness, or fluctuating hearing | Ménière's disease or another inner-ear disorder | Hearing test and ENT | Prompt |
| With heavy bleeding, fatigue, breathlessness, or palpitations | Iron deficiency anemia or another systemic contributor | Clinician who can take a full history and order targeted blood work | Prompt based on severity |
| Changes when you clench your jaw or move your neck | Jaw-joint, muscle, or cervical involvement | Dentist, primary care, audiology, or ENT | Usually routine |
| With new weakness, facial droop, speech change, or severe imbalance | Neurological emergency | Emergency services | Emergency |
Do not turn that table into a self-diagnosis. Use it to make the first appointment more precise.
Build your one-page record with the tracker below →
Why is tinnitus so much worse at night?
Tinnitus usually seems louder at night because there is less outside sound competing with it, not because the ear suddenly deteriorates after dark. Menopause-related insomnia, night sweats, and stress can increase attention and distress, making the same sound harder to ignore. That feedback loop is real, and it is one of the parts you can work on.
Your bedroom at 2 a.m. is the quietest environment you will be in all day. There is less sound to compete with the tinnitus, so the contrast between the ringing and the room rises even when the tinnitus signal has not changed.
Then this happens:
- The sound grabs your attention.
- Attention turns into worry.
- Worry makes sleep harder.
- Less sleep means more fatigue and vigilance tomorrow.
- Tomorrow the sound feels louder.
That loop runs in both directions, which means it can also be interrupted in both directions.
One thing we want to be careful about here. The fact that stress and poor sleep amplify tinnitus does not mean your tinnitus is anxiety. You have almost certainly already been told a version of that, and it landed as a dismissal. It is not one. The sound is real. Attention, arousal, and sleep determine how much territory it takes up.
The Night Loop Check
| What changes after dark? | What that pattern suggests | What to do |
|---|---|---|
| It is louder only when the room becomes quiet, with no new hearing change | Reduced sound competition and increased attention are likely amplifying perception | Use comfortable low-level background sound and keep the medical workup on its normal timeline |
| It spikes after a loud day, concert, tools, or headphones | Recent noise exposure may be part of the pattern | Avoid more loud exposure; seek prompt assessment if hearing changed |
| It becomes pulse-synchronous when you lie down | This is a pulsatile pattern, not merely a sleep problem | Arrange prompt medical assessment |
| It arrives with a sudden hearing drop, vertigo, or neurological symptom | The urgency changed | Use the urgent lane above |
What is reasonable to try tonight, when none of the urgent patterns applies:
- Use comfortable, low-level neutral background sound instead of total silence. A fan, quiet sound machine, or soft environmental audio can work.
- Keep the volume comfortable. The goal is to reduce contrast, not blast over the tinnitus. Loud masking can damage hearing.
- Stop repeatedly checking whether the sound is still there. Every check trains attention back toward it.
- Put nothing in the ear canal — no cotton swabs, oils, or unprescribed drops.
- Keep taking prescribed medicine unless a clinician tells you otherwise.
On caffeine and alcohol: there is no good basis for telling everyone with tinnitus to eliminate both. Track your own response for two weeks. If the same exposure repeatedly changes the symptom for you, that is useful. If it does not, you have spared yourself a pointless restriction.
If night sweats are independently wrecking your sleep, that problem deserves treatment on its own terms. See the menopause sleep guide →
What actually helps tinnitus?
Treatment depends on the cause and on how much tinnitus affects daily life. Treating an identifiable contributor may reduce it. Specialty guidance supports education and counselling, cognitive behavioural therapy for persistent bothersome tinnitus, and a hearing-aid evaluation when hearing loss is documented. There is no FDA-approved medication that specifically treats tinnitus.
Let us get the hard part out of the way: nothing here reliably eliminates the sound for everyone. Any page promising that is selling something.
But no universal cure and nothing helps are very different statements, and the second one is false.
What the guidelines recommend for
| What | For whom | What the goal is |
|---|---|---|
| Education and counselling | Anyone with persistent, bothersome tinnitus | Understand the pattern, reduce fear, and build a management plan |
| Cognitive behavioural therapy (CBT) | Persistent, bothersome tinnitus | Reduce distress, sleep disruption, avoidance, and the amount of attention the sound controls |
| Hearing-aid evaluation | Tinnitus with documented hearing loss | Improve communication and increase useful outside sound |
| Prompt hearing test | One-sided tinnitus, tinnitus lasting 6+ months, or tinnitus with hearing difficulty | Measure the hearing pattern and guide next steps |
| Targeted imaging | Pulsatile tinnitus, focal neurological signs, asymmetric hearing loss, or tinnitus localised to one ear when the clinical evaluation supports it | Look for a structural or vascular cause rather than scan every case |
Source: AAO-HNSF Clinical Practice Guideline: Tinnitus; NICE NG155; NIDCD Tinnitus.
A word on CBT, because the recommendation gets misread constantly. CBT for tinnitus is not a claim that your tinnitus is psychological. It targets the reaction, attention, sleep disruption, and threat response. The sound may remain and life can still get substantially better. That is a real treatment result, not a consolation prize.
A word on hearing aids. This is the practical reason the hearing test comes first. When hearing loss is present, amplifying the outside world can improve communication and make the internal sound less dominant. But you cannot know whether that applies without an audiogram.
Treating an identifiable contributor
Sometimes there is something specific to address — earwax, infection, jaw involvement, medication timing, hearing loss, anemia, or another medical condition. Treating it can reduce or occasionally resolve tinnitus. It does not always. But it is why the assessment is worth doing before you jump straight to coping strategies.
Sound therapy and sleep support
Background sound, hearing devices, and structured sound-based approaches can reduce contrast and help habituation for some people. They should be kept at safe, comfortable levels. A louder device is not a stronger treatment.
Devices and bimodal neuromodulation
One prescription device is worth knowing about, described precisely.
Lenire received FDA De Novo authorisation on 6 March 2023 under DEN210033, creating a new device category. It pairs sound through headphones with mild electrical stimulation on the tongue. Its authorised use is to temporarily relieve tinnitus symptoms in adults 18 and older with at least moderate severity after evaluation by a qualified healthcare professional.
Read that word again: temporarily. Device authorisation is not a cure.
Three caveats belong next to every mention of it:
- The TENT-A3 pivotal study enrolled 112 participants and used a prospective, single-arm, repeated-measures design: six weeks of sound-only treatment followed by six weeks of combined sound-and-tongue stimulation. It was not randomised against a sham device.
- The full-cohort primary endpoint was not met. The clearest signal appeared in participants who still had at least moderate tinnitus after the sound-only phase.
- It requires clinician evaluation, a trained provider, and adherence to a treatment protocol. Evidence specifically in perimenopausal and menopausal women remains thin.
Evidence label: emerging. It is a real authorised option for selected patients, not proof that every person with tinnitus should buy a device.
What does the ENT guideline recommend against?
The AAO-HNSF guideline recommends against ginkgo biloba, melatonin, zinc, and other dietary supplements for persistent bothersome tinnitus. It also recommends against routinely prescribing antidepressants, anticonvulsants, anxiolytics, or intratympanic medication solely to treat tinnitus, and against transcranial magnetic stimulation for routine care. Acupuncture received no recommendation either way.
| Recommended against for routine tinnitus treatment | What the recommendation does — and does not — mean |
|---|---|
| Ginkgo biloba, melatonin, zinc, and other dietary supplements | The panel made an active recommendation against using them for persistent bothersome tinnitus; this is stronger than merely saying evidence is absent |
| Antidepressants, anticonvulsants, anxiolytics, or intratympanic medicines | Do not prescribe them routinely for tinnitus itself. A clinician may still use one for a separate condition such as depression, anxiety, migraine, epilepsy, or sleep disturbance |
| Transcranial magnetic stimulation | Not recommended for routine treatment under the guideline evidence base |
| Acupuncture | No recommendation for or against because the evidence did not support a clear call |
We are including this section for one reason. A meaningful share of what gets marketed to women with menopause tinnitus lives in that first row.
The NIDCD reaches the same practical conclusion from the other direction: commonly marketed vitamins, herbal extracts, and supplements have not been shown to cure tinnitus, and no FDA-approved medication specifically treats tinnitus.
If someone is selling you a pill that promises to switch the ringing off, those two facts are the whole conversation.
If the menopause side of this has been brushed off, that is a separate problem worth fixing — after the ear-specific lane is underway. Midi provides live virtual visits for perimenopause and menopause care in all 50 states and can order blood work or imaging when clinically indicated. As of 4 August 2026, Midi lists $250 for a self-pay initial visit and $150 for continued-care visits; it is in network with most PPO plans, with plan-specific copays, deductibles, and coinsurance. Check Midi coverage and current visit cost → We may earn a commission at no cost to you. How we make money → Honest limitation: Midi does not replace an audiogram or ENT assessment. It is not enrolled with Medicare or Medicaid. Medicare beneficiaries may use Midi only as self-pay and cannot submit related claims; Medicaid and Medi-Cal patients cannot be treated even as self-pay. Verify plan coverage before booking.
Will tinnitus go away after menopause?
There is no reliable menopause-specific timeline. Tinnitus may improve, fluctuate, remain stable, or worsen depending on its contributors, hearing status, duration, treatment, sleep, and distress. Through 4 August 2026, we found no prospective study that follows tinnitus across the menopause transition closely enough to promise it will disappear when hormones settle.
We know that is not the answer you wanted. Here is why we will not give you a better-sounding one.
A comforting sentence appears across menopause content: tinnitus often settles after menopause when hormone levels stop swinging. We looked for the prospective data behind that claim. We did not find a study that can support the promise.
Making a timeline up would be the fastest way to lose your trust.
What we can say is that improvement has more than one meaning, and most of these targets are real:
- The sound becomes quieter
- It happens less often
- You notice it less
- You sleep through it
- You stop being frightened by it
- Communication improves after hearing treatment
- A contributing condition is treated
- It stops controlling your plans, concentration, and mood
That is a realistic target list. It is also what much of tinnitus treatment is actually trying to achieve.
One definition worth having: NIDCD describes tinnitus lasting three months or longer as chronic. That is a definition, not a waiting period. Do not sit on sudden hearing loss, one-sided tinnitus, pulsatile tinnitus, neurological symptoms, or severe distress for three months because of a threshold. Urgency is set by the pattern, not the calendar.
Which clinician should you see first?
The right first contact depends on the pattern. Same-day medical care comes first for sudden hearing loss; emergency care comes first for acute neurological symptoms. An audiologist or ENT handles persistent, one-sided, pulsatile, asymmetric, vertigo-linked, or otherwise complicated patterns. Primary care can examine the ear, review medicines, order targeted tests, and coordinate referrals.
| Who | What they are for |
|---|---|
| Emergency department or urgent same-day medical service | Sudden hearing loss, acute neurological signs, serious head injury, or immediate safety risk |
| Audiologist | Audiogram, speech testing, tinnitus impact assessment, and hearing-aid discussion when hearing loss is documented |
| ENT / otolaryngologist | One-sided, pulsatile, asymmetric, vertigo-linked, or complicated patterns; deciding whether imaging or another specialist is needed |
| Primary care clinician | Ear examination, blood pressure, medication review, history-directed blood work, and referrals |
| Dentist or jaw specialist | Symptoms that reliably change with jaw movement, clenching, grinding, or temporomandibular-joint pain |
| Menopause clinician | The broader menopause treatment decision and review of a tinnitus timeline around an HRT change — without replacing ear-specific care |
Which kind of online care is and is not right for this
Here is where we are going to talk ourselves out of some money, because it is the honest answer.
A symptom whose correct first step is a physical hearing test is not a symptom for questionnaire-only care. If online care is involved, it should either help you book the ear-specific appointment, provide a live history-taking visit with a clinician who can order targeted testing and refer you in person, or handle the separate menopause lane after the hearing plan is clear.
| Care route | Can perform an audiogram? | Can review the medicine and systemic history? | Best use here |
|---|---|---|---|
| Local audiology clinic | Yes | Usually focused on hearing rather than full systemic workup | First-line when the main unresolved question is hearing loss |
| ENT practice | Often on site or by referral | Yes, with ear-specific expertise | One-sided, pulsatile, asymmetric, vertigo-linked, or complicated tinnitus |
| Primary care | Usually no | Yes | Ear exam, medication review, blood pressure, targeted labs, and referrals |
| Live menopause telehealth | No | Yes for the broader menopause and medication history; may order labs and refer | When tinnitus is one of several menopause symptoms, after urgent and ear-specific needs are separated |
| Questionnaire-only HRT care | No | Limited | Wrong starting shape for unexplained tinnitus |
We earn nothing from most audiologists, ENTs, hearing tests, or primary-care referrals. We are still telling you to start there when the pattern calls for it, because that is the right first step.
What should you track and bring to the appointment?
A short, specific timeline is more useful than a long theory about low estrogen. Bring the onset date, which ear, whether it pulses, any hearing or dizziness change, your full medication list including anything stopped, noise exposure, bleeding history, and the decisions you need help making. Two weeks of structured notes can turn a rushed appointment into a usable one.
Track once a day, and any time something changes noticeably. Do not spend all day monitoring it.
The 14-day Ear Symptom Record
| Field | What to note |
|---|---|
| Date and time | When you made the entry |
| Onset | Original start date; sudden or gradual |
| Sound | Ringing, buzzing, hissing, roaring, clicking, or pulsing |
| Side | Left, right, both, or inside my head |
| Loudness (0–10) | Your own scale; subjective is fine |
| How much it bothered you (0–10) | Keep this separate from loudness — it often changes differently |
| Hearing change | None, gradual, sudden, muffled, fluctuating, trouble in noise |
| Pulses with heartbeat? | Yes, no, or unsure |
| Dizziness or balance | None, lightheaded, spinning, unsteady; note duration |
| Ear symptoms | Fullness, pain, drainage, recent infection |
| Sleep | Hours slept and whether tinnitus delayed or interrupted sleep |
| Cycle or menopause context | Bleeding, hot flashes, night sweats; do not hunt for a pattern that is not there |
| Bleeding and anemia clues | Heavy or prolonged bleeding, fatigue, breathlessness, palpitations |
| Headache or migraine | Yes/no, aura, light sensitivity, severity |
| Jaw or neck | Clenching, grinding, pain, or change with movement |
| Noise exposure | What, how loud, and how long |
| Medicines and HRT | Product, dose, route, and any start, stop, or change — read the label rather than trusting memory |
Seven questions to ask
- Do I need a comprehensive hearing test?
- Does this pattern need an ENT referral or imaging?
- Could a medicine, discontinuation, or dose change be contributing?
- Is there a treatable ear, jaw, migraine, hearing, or systemic cause here?
- Given my bleeding and other symptoms, is targeted iron or thyroid testing appropriate?
- What is the goal of any treatment you are proposing — less sound, less distress, better sleep, or better hearing?
- What change would mean I should come back sooner or seek urgent care?
What not to obsessively track: the exact pitch, minute-by-minute fluctuations, elaborate food diaries, or a presumed hormone pattern. Your time is better spent on the fields above.
Make the record before the appointment, not in the waiting room. Copy the table into your notes app or print this page. Put the medication timeline and the seven questions on the first screen. Ten-minute appointments go much further when you walk in three steps ahead.
How did The HRT Index verify this page?
The HRT Index separated clinical guidance, regulatory facts, observational research, and editorial judgement instead of treating every source as equal. Evidence and commercial details were checked through 4 August 2026, and conflicting HRT findings are shown side by side rather than averaged into a false verdict. This page is editorial research and was not medically reviewed by a clinician.
What we actually verified
Read firsthand or checked against the primary source on 4 August 2026:
- NIDCD guidance on tinnitus and sudden sensorineural hearing loss
- AAO-HNSF guideline recommendations for tinnitus and sudden hearing loss
- NICE NG155 referral and management guidance
- The published results and limitations for the studies named in the evidence tables
- Current FDA, DailyMed, and registered-trial information for paroxetine products, venlafaxine, Prometrium, Premarin, Veozah, and Lynkuet
- FDA De Novo details for Lenire and the published TENT-A3 study
- Current patient-facing commercial details for Sesame, Midi, and Find My HRT Path
Provider-stated versus verified
| Claim | Provider-stated source | What we verified on 4 August 2026 | How it is used on this page |
|---|---|---|---|
| Sesame visits start at $34 | Sesame homepage | The homepage displays a platform-wide $34 starting figure | Published only as a platform floor; no ENT or audiology price, service, or availability is assumed |
| Midi self-pay pricing | Midi Pricing & Insurance | $250 initial visit; $150 continued-care visit | Shown with the verification date and without inventing medication, lab, or total-treatment estimates |
| Midi insurance limits | Midi Pricing & Insurance | In network with most PPO plans; coverage varies. Not enrolled with Medicaid or Medi-Cal; those patients cannot use self-pay. Not covered by Medicare; beneficiaries may self-pay but cannot submit claims | Stated beside the CTA, not buried in fine print |
| Find My HRT Path duration and privacy | Live tool page | About 90 seconds, no email or account, nothing sold or stored, answers remain on the page | Used exactly as published; the tool is not presented as tinnitus triage |
What we could not establish — and did not publish as fact
- A general-population estimate showing that one in three perimenopausal or menopausal women have tinnitus
- A randomised placebo-controlled trial showing that menopausal HRT treats tinnitus
- A tinnitus benefit for an estrogen patch, a specific progesterone, a specific progestin, or a compounded hormone product
- A reliable timeline for tinnitus to resolve after menopause
- A universal iron, thyroid, or hormone blood-test panel for tinnitus
- A provider's local ENT or audiology availability, service bundle, or checkout price without the reader's ZIP code and selected listing
What we are not claiming
- That menopause caused your tinnitus
- That any hormone product will improve or worsen it
- That a label or trial report proves a medicine caused it
- That an online menopause visit replaces a hearing test
- That this page was medically reviewed by a clinician — it was not
This page applies The HRT Index Verification Standard: claims are dated, primary sources are preferred, FDA-approved and compounded options are kept strictly separate, commercial facts are distinguished from editorial conclusions, and provider fit is assessed through clinical legitimacy, care quality, medication fit, price transparency, and access. The standard does not use an invented per-provider score on this page.
A licensed clinician makes diagnosis and treatment decisions. Read our medical review policy → · Consumer health data privacy →
What else do women ask about menopause and tinnitus?
The follow-up questions usually fall into four groups: whether hormones caused it, whether HRT will change it, whether a medicine is involved, and which pattern needs faster care. The direct answers below preserve the same rule as the rest of the page: timing can be meaningful without becoming proof, and ear-specific red flags outrank a menopause explanation.
Can perimenopause cause tinnitus?
Perimenopause can coincide with new or changing tinnitus, and hormone effects on the inner ear are biologically plausible. Current human studies do not prove that perimenopause directly causes it. Hearing loss, medicines, noise exposure, migraine, jaw problems, anemia, and ear conditions still need to be considered from the pattern.
Is tinnitus a recognised menopause symptom?
Women do report tinnitus during the menopause transition, and some menopause resources discuss it as a possible associated symptom. It is not specific to menopause, and the largest global prevalence meta-analysis found no significant overall difference between women and men. Treat the timing as a reason to ask better questions, not as a diagnosis.
Can low estrogen cause ringing in the ears?
Lower or fluctuating estrogen could affect inner-ear biology, but low estrogen caused my tinnitus has not been established in humans. Estrogen receptors in the inner ear make the idea plausible. They do not identify the cause in one person, and a blood hormone panel cannot prove it.
Can HRT improve tinnitus?
No hormone therapy is approved for tinnitus, and we found no randomised placebo-controlled trial showing that menopausal HRT treats it. Some small nonrandomised reports describe improvement, while large observational studies conflict. Those findings justify research and a careful timeline review — not starting HRT for the ear symptom.
Can HRT make tinnitus worse?
Tinnitus can change around the same time as HRT for an individual, but the research does not establish a general causal effect. Lee 2017 associated longer HRT duration with more reported tinnitus, while Chen 2018 found fewer diagnosis-coded cases and Hsu 2026 found no independent hearing-threshold association. A personal change deserves review, not an automatic verdict.
Should you stop HRT if tinnitus starts?
No — not based on an article. Contact the prescriber to review the exact timeline, product, dose, route, other medicines, treatment goal, and whether the ear pattern needs prompt assessment. Do not use abrupt stopping and restarting as a self-test.
Can progesterone cause tinnitus?
The current Prometrium label lists tinnitus among postmarketing reports, and older human and animal hearing studies raise a progestogen question. That is a signal, not proof or a prediction. If you have a uterus and take systemic estrogen, do not remove endometrial protection without a clinician-directed alternative.
Can an estrogen patch cause tinnitus?
Tinnitus beginning after a patch start or dose change is a timeline worth reviewing, not proof of cause. Large hearing studies do not establish a tinnitus effect for patches, and no randomised trial has tested an estrogen patch as tinnitus treatment. Do not switch routes on your own to test the theory.
Are compounded hormones better for tinnitus?
No evidence establishes a compounded hormone product as better, safer, or more effective for tinnitus. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing. They should not be treated as equivalent to FDA-approved products on this question.
Can antidepressants used for hot flashes cause tinnitus?
Some paroxetine tablet labels list tinnitus among reported adverse events, and tinnitus also appears in discontinuation warnings for serotonergic antidepressants. The Brisdelle trial registry reports three tinnitus events in 285 women on treatment and none in 285 on placebo, but that small count does not establish an individual cause or stable rate. Product, dose, and timing matter.
Can stopping an antidepressant cause tinnitus?
Yes. Tinnitus is listed among reactions reported after stopping serotonergic antidepressants, particularly abruptly, along with dizziness, sensory disturbances, sleep problems, and other symptoms. Labels advise gradual dose reduction rather than abrupt discontinuation. Never quit one cold because of something you read here.
Why is tinnitus worse at night?
Quiet removes the outside sound that normally competes with tinnitus, so the contrast rises even when the tinnitus itself has not changed. Insomnia, night sweats, and stress can increase attention and distress on top of that. Louder at night does not, by itself, mean the underlying ear problem is rapidly worsening.
Is ringing in one ear a menopause symptom?
Menopause should not be used to explain away new one-sided tinnitus. It needs a prompt hearing assessment, and an ENT may be appropriate depending on the audiogram and examination. Stable one-sided tinnitus is not automatically an emergency, but it is not a pattern to leave unassessed.
What is pulsatile tinnitus, and is it related to menopause?
Pulsatile tinnitus is a whooshing, thumping, or pulsing that matches your heartbeat. It can have vascular, pressure-related, structural, or systemic causes, including anemia in some cases. It should not be assumed to be hormonal and needs prompt medical assessment.
Does iron deficiency cause tinnitus?
A 2025 cohort of women found iron deficiency anemia associated with new diagnosis-coded tinnitus at one year, HR 3.78 (2.60–5.50), with a stronger association in more severe anemia. That is an association, not proof that iron deficiency caused every case or that iron will cure tinnitus. Heavy bleeding and anemia symptoms make the question more relevant.
Do supplements such as ginkgo, melatonin, or zinc help tinnitus?
The AAO-HNSF tinnitus guideline recommends against ginkgo biloba, melatonin, zinc, and other dietary supplements for persistent bothersome tinnitus. NIDCD also states that commonly marketed supplements have not been shown to cure tinnitus. A supplement aisle is not a substitute for a hearing test and pattern-led assessment.
Can a hormone panel tell you whether menopause is causing tinnitus?
No. A hormone result cannot establish the cause of tinnitus, and fluctuating levels make a single test a poor map of perimenopause for most women. Testing can be appropriate in selected clinical situations, but there is no validated hormone panel that diagnoses menopause tinnitus.
Will tinnitus go away after menopause?
There is no reliable menopause-specific timeline and no prospective transition study that supports a promise that it will disappear when hormones stabilise. It may improve, fluctuate, remain stable, or worsen. Treatment can still make it quieter, less intrusive, less frightening, or easier to sleep through.
What tests are used for tinnitus?
Evaluation usually begins with a history, ear examination, medication and noise review, and a hearing test. ENT clinicians may consider imaging for pulsatile tinnitus, focal neurological signs, asymmetric hearing loss, or tinnitus localised to one ear after the clinical assessment. Blood tests should follow the history rather than a fixed tinnitus panel.
Which should you see first — an ENT, audiologist, or menopause clinician?
Sudden hearing loss or acute neurological symptoms need urgent medical care first. Persistent tinnitus usually starts with a hearing assessment; one-sided, pulsatile, asymmetric, vertigo-linked, or complicated patterns may need ENT care. A menopause clinician handles the separate hormone decision and does not replace the ear assessment.
Which sources support this page?
The source list prioritises specialty guidelines, US government health information, FDA records and prescribing information, The Menopause Society, registered trial results, and peer-reviewed human research. Commercial claims are tied to the provider's own pages and dated. Where a study measured hearing loss rather than tinnitus, or diagnosis codes rather than symptoms, the article says so instead of blending the outcomes.
- Jarach CM, Lugo A, Scala M, et al. Global Prevalence and Incidence of Tinnitus: A Systematic Review and Meta-analysis. JAMA Neurology. 2022;79(9):888–900.
- Tunkel DE, Bauer CA, Sun GH, et al. Clinical Practice Guideline: Tinnitus. Otolaryngology–Head and Neck Surgery. 2014;151(2 suppl):S1–S40.
- Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngology–Head and Neck Surgery. 2019;161(1 suppl):S1–S45.
- National Institute on Deafness and Other Communication Disorders. Tinnitus. Updated 1 May 2023. Checked 4 August 2026.
- National Institute on Deafness and Other Communication Disorders. Sudden Sensorineural Hearing Loss. Checked 4 August 2026.
- National Institute for Health and Care Excellence. NG155: Tinnitus — assessment and management. Published 11 March 2020. Checked 4 August 2026.
- The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767–794.
- Curhan SG, Eliassen AH, Eavey RD, Wang M, Lin BM, Curhan GC. Menopause and postmenopausal hormone therapy and risk of hearing loss. Menopause. 2017;24(9):1049–1056. PMID 28486246.
- Lee SS, Han K, Joo YH. Association of perceived tinnitus with duration of hormone replacement therapy in Korean postmenopausal women. BMJ Open. 2017;7:e013736. PMID 28698314.
- Chen HC, Chung CH, Chen VCF, Wang YC, Chien WC. Hormone replacement therapy decreases the risk of tinnitus in menopausal women: a nationwide study. Oncotarget. 2018;9(28):19807–19816. PMID 29731984.
- Hsu JZ, et al. Association of Menopause and Hormone Replacement Therapy With Hearing Loss. Annals of Otology, Rhinology & Laryngology. First published online 6 April 2026. PMID 41943268.
- Yu JN, et al. Association between menstrual cycle irregularity and tinnitus: a nationwide population-based study. Scientific Reports. 2019;9:14038. PMID 31575925.
- Zuriekat M, et al. The link between tinnitus and menstrual cycle disorders in premenopausal women. Scientific Reports. 2025;15:2821. The May 2025 publisher correction addressed affiliations, not the cited results.
- Zhao YX, et al. A preliminary study of the treatment of chronic tinnitus in menopausal women. 2017. PMID 29871277.
- Lai JT, Liu CL, Liu TC. Hormone replacement therapy for chronic tinnitus in menopausal women: our experience with 13 cases. Clinical Otolaryngology. 2017;42(6):1366–1369.
- Liu P, Wei R, Zhu Z, et al. Hormone replacement therapy in perimenopausal women with chronic tinnitus. Journal of Clinical Otorhinolaryngology Head and Neck Surgery. 2021;35(9):812–817. PMID 34628834.
- Fu C, Wang Q, Hao W, et al. Reproductive milestones, use of menopausal hormone therapy, and risk of hearing loss: a life course study of 214,327 women. Maturitas. 2025;201:108685. PMID 40784076.
- Jang Y, Chang Y, Lee J, et al. Hearing changes and trajectories during the menopausal transition and their association with metabolic factors. Maturitas. 2025;201:108686. PMID 40773979.
- Guimaraes P, Frisina ST, Mapes F, Tadros SF, Frisina DR, Frisina RD. Progestin negatively affects hearing in aged women. Proceedings of the National Academy of Sciences. 2006;103(38):14246–14249. PMID 16959884.
- Price K, Zhu X, Guimaraes P, Vasilyeva ON, Frisina RD. Hormone replacement therapy diminishes hearing in peri-menopausal mice. Hearing Research. 2009;252(1–2):29–36. PMID 19269311.
- Hung KC, Weng HL, Lai YC, et al. Iron deficiency anemia and the risk of new-onset tinnitus in female patients: a cohort study. Frontiers in Nutrition. 2025;12:1704946.
- Chen IW, Yu TS, Lai YC, Chang YJ, Hung KC. Association between iron deficiency anemia and risk of hearing loss among female patients. Frontiers in Nutrition. 2025;12:1718261.
- DailyMed. Paroxetine prescribing information search. Current generic-label adverse-event and discontinuation sections checked 4 August 2026.
- DailyMed. Venlafaxine prescribing information search. Discontinuation section checked 4 August 2026.
- DailyMed. Prometrium (progesterone) capsules prescribing information. Current label checked 4 August 2026.
- DailyMed. Premarin prescribing information search. Current oral-tablet adverse-event and postmarketing sections checked 4 August 2026.
- ClinicalTrials.gov. NCT01101841: A 24-week study of low-dose paroxetine for vasomotor symptoms. Results checked 4 August 2026.
- US Food and Drug Administration. Brisdelle prescribing information. Checked 4 August 2026.
- US Food and Drug Administration. FDA approves Veozah for moderate-to-severe vasomotor symptoms. 12 May 2023.
- US Food and Drug Administration. Drug Trials Snapshot: Lynkuet. Approval date 24 October 2025.
- US Food and Drug Administration. Compounding and the FDA: Questions and Answers. Checked 4 August 2026.
- US Food and Drug Administration. De Novo classification request DEN210033 — Lenire. Decision date 6 March 2023.
- Boedts M, et al. Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial. Nature Communications. 2024;15:6933.
- Sesame. Patient-facing homepage. Platform starting-price statement checked 4 August 2026.
- Midi Health. Pricing & Insurance. Pricing, PPO, Medicare, Medicaid, and Medi-Cal statements checked 4 August 2026.
- Midi Health. How Midi Works. Visit format, state availability, and testing or referral statements checked 4 August 2026.
- The HRT Index. Find My HRT Path. Duration, privacy, storage, and routing language checked 4 August 2026.
Related reading: Perimenopause symptoms checklist · Heavy bleeding in perimenopause · HRT benefits and risks · Nonhormonal menopause options · Menopause and sleep
What should you do next?
The ringing being real and the cause being uncertain are not in conflict. You can hold "this might have started during perimenopause" and "I am still getting the pattern assessed" at the same time. The correct next step is set by sudden hearing change, side, pulse, hearing results, and medication timing — not by how convincing the hormone theory feels.
You have been dismissed enough. Go in with a medication timeline, a two-week record, and seven specific questions, and it is a different appointment entirely.
Handle the ear lane first when the pattern calls for it. Handle the menopause lane properly when ringing is one part of a bigger symptom picture. Do not ask one appointment to pretend it is the other.
Still not sure which HRT program is right for you? Take our free 90-second matching quiz.
Get my personalized HRT path →
Find My HRT Path is an educational routing tool. It does not diagnose tinnitus, replace a hearing test, prescribe treatment, or override urgent in-person care. No email or account is required, and your health answers stay on the page.